Roles of Alpha-1 Antitrypsin in Human Health and Disease Models: 2nd Edition
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: 31 January 2027 | Viewed by 129
Editor
Interests: functions and applications of alpha 1 antitrypsin (AAT) and SERPIN; development of novel treatment for autoimmune and inflammatory diseases; gene therapy using recombinant adeno-associated viral vectors (rAAV)
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Following a very successful first run, we are pleased to announce the launch of a second edition of a Special Issue on the roles of alpha-1 antitrypsin in human health and disease models.
Alpha-1 antitrypsin (AAT), a member of serine proteinase inhibitor (SERPIN) superfamily, has multiple functions including the inhibition of proteinases and the regulation of immune system. As a proteinase inhibitor, AAT can reduce tissue damage and degeneration, which is commonly involved in autoimmune and inflammatory diseases. AAT can also interact with immune regulatory molecules and mediate anti-inflammatory effects. Studies have shown that AAT has the therapeutic potential for the treatment of human diseases including AAT deficiency (AATD), graft-versus-host disease (GvHD), type 1 diabetes (T1D), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and COVID-19. However, the mechanism(s) underlying the therapeutic effects of AAT remain elusive. In addition, AAT may have unknown functions to be further investigated. This Specific Issue aims to publish recent findings that advance the therapeutic applications and the functional mechanism(s) of AAT and related molecules.
Prof. Dr. Sihong Song
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- alpha-1 antitrypsin
- serine proteinase inhibitor (SERPIN)
- autoimmunity
- inflammation
- aging
- cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
